CytoMed Therapeutics Limited(GDTC)Earnings, Financials & Key Ratios
GDTC•NASDAQ
$0.99
Price updated Jun 25, 2026
AboutCytoMed Therapeutics Limited, a pre-clinical biopharmaceutical company, focuses on developing novel cell-based immunotherapies for the treatment of human cancers. The company's lead product candidate is CTM-N2D, which consists of expanded gamma delta T cells grafted with natural killer group 2D ligands-targeting chimeric antigen receptor to improve anti-cancer cytotoxicity. It is also developing iPSC-gdNKT, which utilizes iPSC as a starting material to generate gdNKT, a synthetic hybrid of a gamma delta T cell and a NK cell; and CTM-GDT, a product candidate that consists of expanded gamma delta T cells, and exploits the multiple recognition system of gamma delta T cell to recognize and treat a range of cancers. The company was incorporated in 2018 and is headquartered in Singapore.Show more
- Revenue$248K+377.4%
- EBITDA-$3M-31.8%
- Net Income-$3M-61.8%
- EPS (Diluted)-0.26-62.5%
- Gross Margin-277.74%-375.8%
- EBITDA Margin-1346.04%+72.4%
- Operating Margin-1415.96%+72.0%
- Net Margin-1227.07%+66.1%
- ROE-45.21%-81.8%
GDTC Price & Volume
CytoMed Therapeutics Limited (GDTC) stock price & volume — 10-year historical chart
Loading chart...
Persistent Research Burn Outpaces Nascent Revenue
Investment Thesis • Updated 2025Q4
VerdictNegative
Growth:Mixed
Profitability:Negative
Financial Position:Vulnerable
Cash Flow:Burning
Primary Risk:Insufficient liquidity for operations
"CytoMed Therapeutics remains in a high-risk, pre-clinical stage characterized by significant R&D intensity that consistently outstrips its nominal revenue generation. While the company is strategically investing in specialized manufacturing infrastructure to support its gamma delta T cell platform, the rapid depletion of its cash reserves poses a material threat to operational continuity. Investors should monitor the company's ability to secure additional funding, as the current trajectory of widening losses and asset erosion suggests a precarious financial outlook."
Verdict Logic
the company's reliance on depleting its $2.1M cash balance to fund an $1.8M operating loss in 2025Q4 indicates an unsustainable burn rate that necessitates immediate capital infusion.
GDTC Growth Metrics
CytoMed Therapeutics Limited (GDTC) revenue, earnings & EPS growth — 3, 5 & 10-year CAGR
Revenue CAGR
10 Years-
5 Years40.76%
3 Years-
TTM8.27%
Profit CAGR
10 Years-
5 Years-
3 Years-
TTM-64.62%
EPS CAGR
10 Years-
5 Years-
3 Years-
TTM-59.95%
Return on Capital
10 Years-63.68%
5 Years-69.29%
3 Years-49.77%
Last Year-49.5%
GDTC Recent Earnings
CytoMed Therapeutics Limited (GDTC) EPS & revenue vs analyst estimates — last 4 quarters
Q2 2026Latest
May 4, 2026Metric
Actual
Est
EPS
$0.11
—
Rev
$130,625
—
Q4 2025
Sep 30, 2025Metric
Actual
Est
EPS
$0.07
—
Rev
$105,705
—
Q2 2025
Mar 31, 2025Metric
Actual
Est
EPS
$0.05
—
Rev
$74,290
—
Q4 2024
Sep 30, 2024Metric
Actual
Est
EPS
$0.04
—
Rev
$83,257
—
| Quarter | Date | EPS (Act vs Est) | Revenue (Act vs Est) |
|---|---|---|---|
| Q2 2026Latest | May 4, 2026 | $0.11 | $130,625 |
| Q4 2025 | Sep 30, 2025 | $0.07 | $105,705 |
| Q2 2025 | Mar 31, 2025 | $0.05 | $74,290 |
| Q4 2024 | Sep 30, 2024 | $0.04 | $83,257 |
Based on last 12 quarters of dataView full earnings history →
Peers Comparison
Key metrics vs top competitors for CytoMed Therapeutics Limited (GDTC)
| Company | Price | Market Cap | P/E Ratio | Rev Growth (1Y) | Net Margin | ROE | Div Yield |
|---|---|---|---|---|---|---|---|
| $0.99 | $11.71M | -3.81 | 377.39% | -1227.07% | -45.21% | — | |
| $1.87 | $217.97M | -1.63 | -51.24% | -2056.79% | -58.89% | — | |
| $62.03 | $1.21B | -6.38 | -43.89% | -284.18% | -87% | — | |
| $95.93 | $4.68B | -25.38 | — | — | -244.61% | — | |
| $4.21 | $1.51B | -3.86 | 60.6% | -123.9% | -50.17% | — | |
| $53.63 | $8.21B | 19.36 | 87.32% | 65.95% | 87.36% | — |
Compare GDTC vs Peers
CytoMed Therapeutics Limited (GDTC) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
Get notified when GDTC posts new earnings or crosses analyst targets
Free. No account needed. Unsubscribe any time.
GDTC Frequently Asked Questions
CytoMed Therapeutics Limited (GDTC) stock FAQ — growth, dividends, profitability & financials explained
Growth & Financials
What is CytoMed Therapeutics Limited's revenue?
CytoMed Therapeutics Limited (GDTC) reported $0.4M in revenue for fiscal year 2025.
How fast is CytoMed Therapeutics Limited growing?
CytoMed Therapeutics Limited (GDTC) grew revenue by 377.4% over the past year. This is strong growth.
Is GDTC profitable?
CytoMed Therapeutics Limited (GDTC) reported a net loss of $4.1M for fiscal year 2025.
Dividend & Returns
What is GDTC's return on equity?
CytoMed Therapeutics Limited (GDTC) has a return on equity (ROE) of -45.2%. Negative ROE indicates the company is unprofitable.
What is CytoMed Therapeutics Limited's free cash flow?
CytoMed Therapeutics Limited (GDTC) had negative free cash flow of $4.7M in fiscal year 2025, likely due to heavy capital investments.